Clinical Trials Browser

sargramostim × Plasma cell × 30 days × Clear all

NCT02334865 2026-05-15

SVN53-67/M57-KLH Peptide Vaccine in Treating Patients With Newly Diagnosed Multiple Myeloma Receiving Lenalidomide Maintenance Therapy

Phase 1 Active not recruiting

Other hematologic neoplasmPlasma cell

Leukemia, Plasma Cell, Multiple Myeloma